Search Results

1 - 10 of 12 items :

  • "performance" x
  • Paediatric Haematology and Oncology x
Clear All
The prognostic value of mean platelet volume in cancer patients

a low MPV/PC ratio was an independent unfavorable predictive factor for OS [ 20 ]. Furthermore, in locally advanced (stage IIIA/B) inoperable NSCLC MPV, as well as PLT and ECOG performance score were found as the most significant independent factors affecting survival ( p < 0.001, p = 0.008, and, p = 0.034, respectively) [ 21 ]. Whereas, in epidermal growth factor receptor (EGFR) mutant lung adenocarcinoma, the MPV level not only influence prognosis but also predict the outcome of EGFR tyrosine kinase inhibitor (TKI) therapy. In this type of cancer, high MPV

Open access
Study of CD25 expression on leukemic cells: a prognostic factor in acute myeloid leukemia

1 Introduction Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by the clonal expansion of myeloid blasts in the peripheral blood, bone marrow, and/or other tissues, with maturation arrest of cells in the bone marrow and impaired production of normal blood cells [ 1 , 2 ]. Treatment strategies of patients with AML are based on various prognostic factors, including age and performance status of the patient, as well as cytogenetic and molecular characteristics of the leukemic clone [ 3 ]. To date, cytogenetic

Open access
Nivolumab for relapsed/refractory classical Hodgkin lymphoma after brentuximab vedotin failure – Polish Lymphoma Research Group real-life experience

histopathological assessment of tissue samples excised before the first-line therapy [ 15 ]. At baseline staging according to Ann Arbor classification, Eastern Cooperative Oncology Group performance status (ECOG PS) and International Prognostic Index (IPI) were assessed. Patients received nivolumab intravenously over 60 minutes at 3 mg/kg every 2 weeks until disease progression or unacceptable toxicity. Efficacy data including overall response rate (ORR), complete remission (CR) rate, progression-free survival (PFS) and overall survival (OS) as well as the safety data were

Open access
Evaluation of the prognostic and predictive value of free light chains in patients with chronic lymphocytic leukemia – preliminary results

. Clin Chem Lab Med 2016;54:1073–83. Barnidge DR Dispenzieri A Merlini G et al Monitoring free light chains in serum using mass spectrometry Clin Chem Lab Med 2016 54 1073 – 83 [14] Hansen CT. Performance goals for immunoglobulins and serum free light chain measurements in plasma cell dyscrasias can be based on biological variation. Clin Chem Lab Med 2016;54:1031–3. Hansen CT Performance goals for immunoglobulins and serum free light chain measurements in plasma cell dyscrasias can be based on biological variation Clin Chem Lab Med 2016 54

Open access
Terapia manualna po alloplastyce stawu kolanowego u pacjenta z artropatią hemofilową w przebiegu hemofilii A – studium przypadku

;4:121– 8. 22662297 10.4055/cios.2012.4.2.121 Kamath AF Horneff JG Forsyth A Nikci V Nelson CL Total knee arthroplasty in hemophiliacs: gains in range of motion realized beyond twelve months postoperatively Clin Orthop Surg 2012 4 121 8 [17] Vallejo L, Pardo A, Gomis M, Gallach JE, Pérez S, Querol F. Influence of aquatic training on the motor performance of patients with haemophilic arthropathy. Haemophilia 2010;161:155–61. Vallejo L Pardo A Gomis M Gallach JE Pérez S Querol F Influence of aquatic training on the

Open access
Combination Therapies of Hypomethylating Agents for Elderly Patients with Acute Myeloid Leukemia

Introduction Acute myeloid leukemia (AML) is an aggressive hematopoietic malignancy, characterized by abnormal proliferation of progenitor cells. Age is a fundamental risk factor, with median overall survival (OS) < 6 months for elderly patients with AML receiving intensive therapy [ 1 ]. Several measurable and immeasurable factors, including poor performance status, adverse cytogenetics, genetic mutations, and complications, are responsible for poor prognosis [ 2 , 3 , 4 , 5 ]. DNA methylation has been demonstrated to silence tumor suppressor

Open access
Use of MPV and MPV/Plt Ratio in the Differentiation of Migraine and Tension-Type Headache

and TTH was determined to be 0.037, and the sensitivity was 92.5% and specificity was 55% for this value. Primary headaches comprise a health problem that causes the loss of capacity and performance. For this reason, accurate diagnosis and administration of suitable treatment is important. Since the diagnosis of migraine and other primary headaches depends only on the medical history obtained from the patient, clinicians have a hard time and, sometimes, they may apply the wrong treatment. TTH is the most common headache around the world; however, different

Open access
Abnormal hemostasis screening tests leading to diagnosis of multiple myeloma

assays does not always reflect the real coagulation status in vivo. Coagulation disturbances, however, tend to increase with the progress of the disease [ 25 ]. Authors’ contributions/ Wkład autorów TI – performance of laboratory tests, data analysis, writing the manuscript. JZ – clinical assessment of the patient, reviewing the manuscript. AJ – clinical assessment of the patient, data analysis, reviewing the manuscript. Conflict of interest Conflict of interest/ Konflikt interesu: We declare no conflict of interest Financial support

Open access
Coexistence of hemoglobin Handsworth and alpha 3.7 kb deletion in Caucasian woman in Poland

origin [ 7 ]. It was also detected in a British patient [ 8 ], an Iran patient [ 3 ] and an inhabitant of the Netherlands [ 9 ]. In HPLC (high-performance liquid chromatography) analysis as well as in other routine laboratory methods the hemoglobin coded by DNA with this mutation, can be mistaken with HbS since both elute in the “S” window compartment [ 10 ]. The aim of this communication is to highlight the occurrence of compound hetreozygotes in α-globin gene defects in Northern Europe. Materials and methods A 32-year-old Polish woman was diagnosed for red

Open access
Plerixafor for patients who fail cytokine-or chemotherapy-based stem cell mobilization: Results of a prospective study by the Polish Lymphoma Research Group (PLRG)

/μL after 1st dose of plerixafor (median, range) 25.5 (0.2-708.4) 13.2 (0.2-57) 28.3 (20-75) 68.1 (11-708.4) Fold increase 3.3 (0.3-155) 6.1 (0.7-155) 4.5 (2.2-8.3) 2.1 (0.3-7.7) The analysis was restricted to 81 patients with available data. Factors affecting efficacy of mobilization with the use of plerixafor A univariate analysis was performed to evaluate associations of potential prognostic factors with the rate of successful mobilization. The following factors were analyzed: age, performance status, type of mobilization

Open access